1. The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma
- Author
-
Kangshun Zhu, Zai-bo Jiang, Zhengran Li, Hong Shan, Bo Zhang, and Dan Li
- Subjects
Cancer Research ,Carcinoma, Hepatocellular ,Transplantation, Heterologous ,Antineoplastic Agents ,Apoptosis ,Biology ,Mesenchymal Stem Cell Transplantation ,TNF-Related Apoptosis-Inducing Ligand ,Mice ,In vivo ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Bioluminescence imaging ,Tropism ,Pharmacology ,Cisplatin ,Liver Neoplasms ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Genetic Therapy ,Flow Cytometry ,medicine.disease ,Gene Expression Regulation, Neoplastic ,Transplantation ,Oncology ,Drug Resistance, Neoplasm ,Hepatocellular carcinoma ,Immunology ,Cancer research ,Molecular Medicine ,Stem cell ,Research Paper ,medicine.drug - Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been demonstrated to induce cell apoptosis in many types of tumors, while many hepatocellular carcinoma (HCC) cells display high resistance to TRAIL. Another outstanding limitation of TRAIL is the short half-life in vivo. Stem cell-based therapies provide a promising approach for the treatment of many types of tumors because of the ability of tropism. Therefore, as a new therapeutic strategy, the combination of chemotherapeutic agents and TRAIL gene modified MSCs (TRAIL-MSCs) would improve the therapeutic efficacy of HCC in vivo. This is the first time to show the potential of combination of chemotherapeutic agents and MSCs as a gene vector in the therapy of HCC.
- Published
- 2012